Much of the research that has been done on prostate cancer tissue biomarkers has relied on radical prostatectomies for biospecimens. However, it is well recognized that important groups of patients are under-represented or missing entirely from biorepository collections of radical prostatectomy specimens. Using prostate biopsy tissues for molecular biomarker research significantly expands the range of available patients to include men whose biopsies show no cancer as well as men who are treated non-surgically or who choose active surveillance. However, one of the challenges of biopsy-based biomarker research is the limited amount of tissue that can be obtained from each core. To address this challenge, we have developed and fully implemented innovative biopsy tissue print technologies that allow us to obtain high quality RNA and DNA from each biopsy core without compromising the specimen for a pathologic diagnosis. Prostate biopsy tissue print samples have been successfully utilized for gene expression profiling, genotyping, DNA methylation and sequencing analyses. Emerging biopsy tissue print applications include studies using viable cells to study tumor metabolism and drug response.